Mobocertinib
- Business Wire
Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
− Prescription Drug User Fee Act (PDUFA) Target Action Date Set for October 26, 2021 CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS…
Read More » - Business
Takeda FY2020 H1 Results Demonstrate Portfolio Resilience; Confirms Full-Year Management Guidance & Raises Forecasts for Free Cash Flow, Reported OP & Reported EPS
Osaka, Japan: FY2020 H1 results driven by growth of global brands (e.g. Entyvio +25.8% YOY, TAKHZYRO +45.5% YOY, NINLARO +…
Read More » - Health
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress
Osaka, Japan & Cambridge, Mass., United States: − Key Results from Phase 3 ALTA 1L Sub-Analyses Further Support ALUNBRIG’s Strong Intracranial…
Read More »